MCL1 and acute myeloid leukemia: We previously reported that although the specific MCL-1 binding inhibitor A-1210477 produced a supra-additive effect in combination with Venetoclax in AML cells, it failed to prime to BAD-BH3 peptide in a BH3 profiling assay [11].